Advertisement


Benjamin Besse, MD, PhD, and Tony Mok, MD, on Results of the BIRCH Clinical Trial

2015 European Cancer Congress

Advertisement

Benjamin Besse, MD, PhD, of the Institut Gustave Roussy, and Tony Mok, MD, of The Chinese University of Hong Kong, discuss this phase II trial of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1–selected NSCLC (Abstract 17LBA).



Related Videos

Skin Cancer

Shailender Bhatia, MD, on Merkel Cell Carcinoma: Final Results of a Phase II Study

Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).

Kidney Cancer

Brian I. Rini, MD, on A Cancer Vaccine for Renal Cell Carcinoma

Brian I. Rini, MD, of the Cleveland Clinic Taussig Cancer Institute, discusses the results from a phase III study investigating a multipeptide cancer vaccine in patients receiving ...

Prostate Cancer

A. Oliver Sartor, MD, on Results of the ALSYMPCA Trial for Castration-Resistant Prostate Cancer

A. Oliver Sartor, MD, of Tulane University School of Medicine, discusses the latest results of a clinical trial on radium-223 dichloride and the improvement in overall survival of ...

Rolf A. Stahel, MD, on Results From the BELIEF Trial

Rolf A. Stahel, MD, of University Hospital, Zurich, discusses this phase II trial of erlotinib and bevacizumab in patients with advanced, EGFR-mutated non-small cell lung ...

Issues in Oncology
Breast Cancer

Matteo Lambertini, MD, on Preserving Women’s Fertility Through Hormonal Therapy

Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast ca...

Advertisement

Advertisement



Advertisement